This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 16% and 7.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Soars 5.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -38.24% and 5.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Twist Bioscience (TWST) delivered earnings and revenue surprises of 16.92% and 9.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 9.86% and 0.13%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Codiak BioSciences, Inc. (CDAK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Codiak BioSciences, Inc. (CDAK) delivered earnings and revenue surprises of 55% and 0.83%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
by Zacks Equity Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -10.00% and -15.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.06% and 43.04%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of 22.95% and -91.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?